Targacept (NASDAQ:TRGT), already in the midst of a corporate restructuring, must now also search for a new CEO. Don deBethizy is resigning from his positions as CEO and chairman of the drug development company. In a statement, deBethizy said he “decided to step down for personal considerations.” But the move follows some setbacks for the […]
Targacept’s (NASDAQ:TRGT) drug development effort is focused on the here, now and soon to be future. It has to be because a corporate restructuring that will lead to layoffs of 65 workers — nearly half of Targacept employees — has had particular impact on the company’s preclinical research. That means Targacept will need to […]
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Targacept‘s (NASDAQ:TRGT) first quarter dealt the company several blows with a phase 3 clinical trial failure for its lead drug candidate and a missed target in another clinical program. Failure of depression candidate TC-5214 led to the formal termination of the company’s partnership with AstraZeneca (NYSE:AZN) on that compound. Rights to TC-5214 revert to Targacept […]
Targacept (NASDAQ:TRGT) is slashing its workforce by nearly half, part of a restructuring plan that comes one month after its lead drug candidate, a depression drug, failed the last of a series of phase 3 clinical trials. The company is laying off 65 employees, approximately 46 percent of its staff. Also departing the company will […]
The asthma treatment Targacept (NASDAQ:TRGT) is developing actually did not perform as well in clinical trials as initially thought. Targacept last month released top-line phase 2 results for TC-6987 that showed the asthma compound met both goals in the clinical trial. But the Winston-Salem, North Carolina drug developer has revised its top-line results and said […]
A Targacept (NASDAQ:TRGT) compound developed for potential applications in asthma and type 2 diabetes has mixed mid-stage clinical trial results that show success in asthma but failure in diabetes. As a result, Targacept will no longer pursue TC-6987 in the diabetes indication. The mixed results come a week after the Winston-Salem, North Carolina company reported […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Targacept (NASDAQ:TRGT) and AstraZeneca (NYSE:AZN) are dropping plans to seek regulatory approval on their depression drug candidate after the compound failed its remaining phase 3 clinical trials. The two drug companies were developing TC-5214 as an adjunct treatment to treat major depressive disorder in patients who did not adequately respond to the first line of […]
Depression treatment TC-5214 remains Targacept‘s (NASDAQ:TRGT) lead drug candidate and perhaps it was with that in mind that CEO Don DeBethizy started the earnings conference call with an update on that drug program. But there was nothing new for the company to report on TC-5214 since disclosing in December the failure of the compound in […]
Targacept (NASDAQ:TRGT) has seen two phase 3 clinical trial failures in the last two months for its depression drug candidate. Now the company has some better news, albeit for a different indication. Drug partner AstraZeneca (NYSE:AZN) will take on a Targacept Alzheimer’s disease drug candidate for further clinical studies. AstraZeneca will conduct and fund phase […]
The depression treatment that Targacept (NASDAQ:TRGT) has identified as its lead drug candidate has failed in a phase 3 clinical trial, the second failure in less than two months for the compound. Put simply, the drug candidate TC-5214 was no better than a placebo in the late-stage trial. If Targacept is to see success for […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Drug development company Targacept (NASDAQ:TRGT) has started two mid-stage clinical trials on a compound that could have applications in schizophrenia as well as attention deficit-hyperactivity disorder. It’s the second round of phase 2 trials for the compound from Winston-Salem, North Carolina-based Targacept. Earlier this year, TC-5619 showed positive results in a phase 2 trial that […]
Targacept (NASDAQ:TRGT) remains committed to moving forward with three more phase 3 clinical trials attempting to develop depression’s first new treatment mechanism in decades despite results of one trial showing that the compound partnered with AstraZeneca (NYSE:AZN) performed no better than a placebo. CEO Don deBethizy said he could not explain why TC-5214 did not […]
Current medical news from today, including promising AstraZeneca/Targacept depression drug fails in first Phase III trial, changes at Amag Pharmaceuticals, and a 3D endoscopy.
When Targacept (NASDAQ:TRGT) and AstraZeneca (NYSE:AZN) changed their collaboration agreement in 2007 by adding a new compound being studied in cognitive disorders, the addition was done as an option deal. Winston-Salem, North Carolina-based Targacept got $2 million up front. If TC-5619 achieved clinical proof of concept, AstraZeneca had the option to pay $40 million for […]
A Targacept (NASDAQ:TRGT) compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca (NYSE:AZN) has started in mid-stage clinical studies as a potential new Alzheimer’s disease treatment. Winston-Salem, North Carolina-based Targacept is studying AZD3480 in patients with mild to moderate Alzheimer’s disease. The study is part of a special protocol […]